Imiquimod 5% cream: a new treatment option for basal cell carcinoma.
Salasche
Stuart
S
Department of Medicine, Section of Dermatology, University of Arizona Health Sciences Center, Arizona, USA.
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000634:Aminoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D017252:CD3 Complex / Q000378:metabolism; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D016207:Cytokines / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D000077271:Imiquimod; D007371:Interferon-gamma / Q000378:metabolism; D007378:Interleukins / Q000378:metabolism; D018225:Neoplasms, Fibroepithelial / Q000473:pathology; D011956:Receptors, Cell Surface / Q000172:deficiency / Q000502:physiology; D012878:Skin Neoplasms / Q000188:drug therapy*; D018417:Th1 Cells / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D017252:CD3 Complex; D016207:Cytokines; D007378:Interleukins; D011956:Receptors, Cell Surface; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D000077271:Imiquimod